MedTrace Logo

Real World Effectiveness of Oral Semaglutide in Thailand Participants With Type 2 Diabetes

NCT06507475 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 209

Last updated 2025-12-30

No results posted yet for this study

Summary

This study aims to describe the effectiveness of oral semaglutide on glycemic control and body weight control and describe characteristics of type 2 diabetes (T2D) adult patients who are being treated with oral semaglutide in Thailand. Data of eligible patients with T2D will be collected via electronic medical record or paper-format chart review to assess the effectiveness of oral semaglutide. Total study duration for the individual patient will be six months from baseline. The study duration expands within the window period will be 12 months from baseline which will be the optional visit.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

Semaglutide

Participants treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician.

Sponsors & Collaborators

Principal Investigators

  • Clinical Transparency (dept. 2834) · Novo Nordisk A/S

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-07
Primary Completion
2024-12-20
Completion
2024-12-20

Countries

  • Thailand

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06507475 on ClinicalTrials.gov